NDAINTRAMUSCULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Clinical Trials (5)
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Started Jan 2024
231 enrolled
Breast Cancer
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy
Started Apr 2023
167 enrolled
Prostate Cancer
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Started Nov 2022
195 enrolled
Advanced Prostate CancerMetastatic Prostate CancerLocally Advanced Prostate Cancer
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
Started Aug 2022
147 enrolled
Prostate Cancer
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
Started Jun 2022
450 enrolled
Early-stage Breast Cancer
Loss of Exclusivity
LOE Date
Jun 30, 2029
40 months away
Patent Expiry
Jun 30, 2029
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10166181 | Jun 30, 2029 | Product | — |
Company
R-Pharm US
NJ - Princeton